ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

Presenters: Matt Zierhut, Certara and Jonathan French, Johnson & Johnson

Matt and Jonathan’s roundtable, “Use of Model-Based Meta-Analysis (MBMA) to Better Integrate Multiple Data Sources in Drug Development,” is organized by the Statistics and Pharmacometrics (SxP) Special Interest Group (SIG). The session will focus on how Model-Based Meta-Analysis (MBMA) enables sponsors to integrate evidence across clinical trials and external data sources to improve development decisions, optimize trial design, and strengthen regulatory strategies. The discussion also supports the SxP Special Interest Group’s mission of fostering closer collaboration between statisticians and pharmacometricians while advancing the use of quantitative methods in model-informed drug development (MIDD).

Find additional details on the workshop and view the complete program here.